Author:
Gribble M J,Chow A W,Naiman S C,Smith J A,Bowie W R,Sacks S L,Grossman L,Buskard N,Growe G H,Plenderleith L H
Abstract
Piperacillin as a single agent was compared in a prospective randomized trial with carboxypenicillin-aminoglycoside combinations in empirical therapy of serious bacterial infections. The difference in the clinical response rates with piperacillin (77% of 26 infection episodes) and combination therapy (75% of 24 infection episodes) were not statistically significant. Fewer adverse effects occurred in the piperacillin-treated group (42%) than in the combination-treated group (71%) (P = 0.0399 by Fisher's exact test), although neither nephrotoxicity nor hypokalemia alone was significantly less frequent in patients receiving piperacillin. However, the emergence of resistant organisms during therapy was more frequent among patients receiving piperacillin alone (42% of patients) than among patients receiving combination therapy (17% of patients) (P = 0.465 by Fisher's exact test). Moreover, emergence of resistance accounted for 5 of 9 patients with treatment failure, superinfection, or both when piperacillin was used as a single agent, compared with 2 of 10 similar patients in the combination group (P = 0.1299 by Fisher's exact test). The use of piperacillin as a single agent in the treatment of serious bacterial infections is not advocated, and the addition of an aminoglycoside to prevent emergence of resistance during empirical therapy of such infections is strongly recommended.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference21 articles.
1. Piperacillin susceptibility tests by the single-disk agar diffusion technique;Barry A. L.;Antimicrob. Agents Chemother.,1979
2. Piperacillin: in vitro evaluation;Bodey G. P.;Antimicrob. Agents Chemother.,1978
3. Dowell V. R. Jr. and A. C. Sonnenwrth. 1974. Grampositive nonsporeforming anaerobic bacilli p. 396-401. In E. H. Lennette E. H. Spaulding and J. P. Truant (ed.) Manual of clinical microbiology 2nd ed. American Society for Microbiology Washington D.C.
4. Comparative in vitro activity of ceftizoxime, cefoperazone, and cefoxitin against anaerobic bacteria;Drulak M. W.;Antimicrob. Agents Chemother.,1981
5. Ewing W. H. and W. J. Martin. 1974. Enterobacteriaceae p. 189-221. In E. H. Lennette E. H. Spaulding and J. P. Truant (ed.) Manual of clinical microbiology 2nd ed. American Society for Microbiology Washington D.C.
Cited by
108 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献